

## AKIN Criteria for Acute Kidney Injury in Critically Ill Cirrhotic Patients

Ahmed Alsherif<sup>1</sup>, Hisham Darwesh<sup>1</sup>, Mervat Eldamarawy<sup>1</sup>, Ahmed Shawky<sup>2</sup>, Azza Emam<sup>2</sup> and Maha Mohsen<sup>2</sup>

<sup>1</sup> Critical Care Department, Theodor Bilharz Research Institute (TBRI)

<sup>2</sup> Department of Medicine, University of Ain Shams

[Drwesh123@yahoo.com](mailto:Drwesh123@yahoo.com)

**Abstract: Background.** The Acute Dialysis Quality Initiative Group has published a consensus definition/classification system for acute kidney injury (AKI) termed the RIFLE criteria. The Acute Kidney Injury Network (AKIN) group has recently proposed modifications to this system. It is currently unknown whether there are advantages between these criteria. **Methods .**We interrogated 100 Adult critically ill cirrhotic patients for which RIFLE and AKIN criteria were done. **Aim of the work.** Comparison of RIFLE and AKIN criteria for AKI in critically ill cirrhotic Patients. **Results.** This study was performed on 100 cirrhotic patients admitted to Intensive Care Unit in the hospital of Theodore Bilharz Research Institute. According to the RIFLE classification, there were 40 Non-ARF patients, 22 RIFLE-R patients, 8 RIFLE-I patients and 30 RIFLE-F patients. According to AKIN criteria there were 38 Non-ARF patients, 24 (Stage 1) patients, 8 (Stage 2) patients and 30 (Stage 3) patients. The Non-Survivor group had a significantly longer duration of hospital stay than the Survivor group. There was insignificant correlation between RIFLE / AKIN score and the LOS (length of stay) as the  $R= 0.135$  and  $p$  value = 0.179. RIFLE and AKIN classifications studied in this study were highly predictive of poor outcome in cirrhotic patients at different cut-off points as studied by ROC curve analysis. The patients' ages were ranging from 43 to 73 with a mean age of  $59 \pm 8.06$  years. **Conclusion.** Compared to the RIFLE criteria, the AKIN criteria do not materially improve the sensitivity, robustness and predictive ability of the definition and classification of after admission to ICU.

Ahmed Alsherif, Hisham Darwesh, Mervat Eldamarawy, Ahmed Shawky, Azza Emam and Maha Mohsen. **AKIN Criteria for Acute Kidney Injury in Critically Ill Cirrhotic Patients.** *Life Sci J* 2014;11(9):159-165] (ISSN:1097-8135). <http://www.lifesciencesite.com>. 22

**Keywords** acute kidney injury; acute renal failure; AKIN; critically ill; RIFLE.

### 1. Introduction

Liver cirrhosis represents the final common pathway of virtually all chronic liver disease and is characterized by an accumulation of extracellular matrix rich in fibrillar collagen (1).

A feature of liver cirrhosis is the existence of disturbances in systemic circulation characterized by marked arterial vasodilation that occurs principally in the splanchnic circulation and generates a reduction in total peripheral vascular resistance and arterial pressure and a secondary increase in cardiac output. These abnormalities are central to the development of several major complications of cirrhosis, such as hepatorenal syndrome, ascites, spontaneous bacterial peritonitis, dilutional hyponatremia, and hepatopulmonary syndrome. Renal failure is the most clinically relevant of these conditions as its appearance generally indicates very poor prognosis (2- 5).

Elevated serum creatinine (SCr) levels of  $> 1.3$  or  $1.5$  mg/dl have been identified as a predictor of poor prognosis in patients with advanced liver cirrhosis (6).

The common used scoring systems for predicting the outcome in critically ill cirrhotic patients, such as Child-Pugh score (7), Sequential Organ Failure Assessment (SOFA) (8), Model for

End-stage Liver Disease (MELD) (9), and Acute Physiology, Age, Chronic Health Evaluation II (APACHE II) (10) evaluate renal function according to the serum creatinine.

The RIFLE (risk of renal failure, injury to the kidney, failure of kidney function, loss of kidney function, and end-stage renal failure) classification was first proposed by the Acute Dialysis Quality Initiative (ADQI) group at the second ADQI conference in Vicenza, Italy, in May 2002, in an attempt to standardize the study of ARF. The RIFLE criteria classify ARF into three groups (risk, injury, and failure) according to changes in SCr and urine output (UO) (Table 1). The RIFLE classification has been evaluated in a number of clinical studies of critically ill patients with AKI. In general, these criteria have been found to have clinical relevance for the diagnosis of AKI, classifying the severity of AKI and for monitoring the progression of AKI, as well as having modest predictive ability for mortality (11-14).

More recently, the Acute Kidney Injury Network (AKIN) group (Table 2), an international collaboration of nephrologists and intensivists, has proposed refinements to the RIFLE criteria. In particular, the AKIN group sought to increase the

sensitivity of the RIFLE criteria by recommending that a smaller change in serum creatinine (0.3 mg/dl) be used as a threshold to define the presence of AKI and identify patients with stage I AKI (analogous to

RIFLE-Risk). It is currently unknown whether discernible advantages exist with one approach to definition and classification versus the other.

**Table 1:** The Acute Dialysis Quality Initiative (ADQI) criteria for the definition and classification of AKI (i.e. RIFLE criteria)

RIFLE	Serum Creatinine Criteria	Urine Output Criteria
Risk	Increase in serum creatinine $\geq 1.5X$ baseline or decrease in GFR $\geq 25\%$	$<0.5$ mL/kg/h for $\geq 6$ h
Injury	Increase in serum creatinine $\geq 2.0X$ baseline or decrease in GFR $\geq 50\%$	$<0.5$ mL/kg/h for $\geq 12$ h
Failure	Increase in serum creatinine $\geq 3.0X$ baseline or decrease in GFR $\geq 75\%$ or an absolute serum creatinine $\geq 354$ $\mu\text{mol/L}$ with an acute rise of at least $44$ $\mu\text{mol/L}$	$<0.3$ mL/kg/h $\geq 24$ h or anuria $\geq 12$ h

**Table 2:** The proposed Acute Kidney Injury Network (AKIN) criteria for the definition and classification of AKI

AKIN	Serum Creatinine Criteria	Urine Output Criteria
Stage 1	Increase in serum creatinine $\geq 26.2$ $\mu\text{mol/L}$ or increase to $\geq 150$ – $199\%$ (1.5- to 1.9-fold) from baseline	$<0.5$ mL/kg/h for $\geq 6$ h
Stage 2	Increase in serum creatinine to 200–299% ( $>2$ – $2.9$ fold) from baseline	$<0.5$ mL/kg/h for $\geq 12$ h
Stage 3	Increase in serum creatinine to $\geq 300\%$ ( $\geq 3$ -fold) from baseline or serum creatinine $\geq 354$ $\mu\text{mol/L}$ with an acute rise of at least $44$ $\mu\text{mol/L}$ or initiation of RRT	$<0.3$ mL/kg/h $\geq 24$ h or anuria $\geq 12$ h

### Aim of study:

The aim of this study is to evaluate and compare RIFLE and AKIN criteria in evaluating AKI and predicting mortality in critically ill cirrhotic patients.

### 2. Patients and Methods:

This study will be performed on 100 cirrhotic patients admitted to Intensive Care Unit in the hospital of Theodore Bilharz Research Institute. Exclusion criteria are:

- \* Pediatric patients  $\leq 18$  years of age.
- \* Uremic patients undergoing renal replacement therapy.
- \* Patients who had undergone liver transplantation.

The following data will be collected for each patient on the 1<sup>st</sup> day of admission:

- Demographics.
- Reason for ICU admission.
- RIFLE classification.
- AKIN Classification.

And finally, the duration of hospitalization and the outcome of each patient will be recorded.

### Statistical Analysis

Diagnosis of cirrhosis was based on a combination of physical findings and biochemical and sonar findings. Severity of liver disease on ICU admission was graded using Child-Pugh and SOFA scoring systems.

Continuous variables were summarized using means and standard error. The primary analysis compared hospital survivors with non-survivors. All variables were tested for normal distribution using the Kolmogorov–Smirnov test. Student's *t*-test was employed to compare the means of continuous variables and normally distributed data; otherwise, the

Mann–Whitney *U*-test was employed. Categorical data were tested using the chi-square test. Finally, risk factors were assessed with univariate analysis, and variables that were statistically significant ( $p < 0.05$ ) in the univariate analysis were included in multivariate analysis by applying a multiple logistic regression based on forward elimination of data.

### 3. Results

The patients' ages were ranging from 43 to 73 with a mean age of  $59 \pm 8.06$  years. Regarding gender distribution 68% were males and 32% were females as shown in table (3):

Table 3	Number	Percent
MALE	68	68%
FEMALE	32	32%

According to the RIFLE classification, there were 40 Non-ARF patients, 22 RIFLE-R patients, 8 RIFLE-I patients and 30 RIFLE-F patients as shown in table (4):

Table 4	Survivor	Non-Survivor	Total
Non-ARF	27	13	40
Risk	7	15	22
Injury	2	6	8
Failure	2	28	30

According to the AKIN criteria, there were 38 Non-ARF patients, 24 (Stage 1) patients, 8 (Stage 2) patients and 30 (Stage 3) patients as shown in table (5):

Table 5	Survivor	Non-Survivor	Total
Non-ARF	26	12	38
Stage 1	8	16	24
Stage 2	2	6	8
Stage 3	2	28	30

Morbid and Co-morbid conditions: Table (6):

Table 6		Number	Percent
Diabetes Mellitus	No DM	67	67%
	DM	33	33%
Hypertension	No HTN	84	84%
	HTN	16	16%
Hepatocellular Carcinoma	No HCC	80	89%
	HCC	10	11%

**Laboratory values of the studied population:**

The mean values of laboratory data with Standard deviation are shown in table (7):

Table 7	N	Mean	±Std. Deviation
BUN	100	38.64	23.30
Na	100	130.03	7.35
K	100	4.41	.725
AST	100	70.23	57.95
ALT	100	35.90	23.95
Albumin	100	2.05	0.44
Bilirubin	100	6.70	5.88
Hb	100	8.79	1.43
WBC	100	10.43	6.15
Platelets	100	120.46	71.87
PT	100	18.54	2.70
INR	100	1.67	0.26
PH	100	7.35	0.10
PO2	100	83.06	17.75
PCO2	100	26.36	5.81
HCO3	100	16.77	4.80
Hct	100	24.90	6.65
Creatinine at baseline	100	0.96	0.27
Creatinine on follow up	100	1.89	1.23

**Length of hospital stay:**

The mean duration of hospital stay in the whole studied population was 11.6± 6.58 days with least of 3 days and maximum 30 days.

**Mortality in the whole studied population:**

There were 62% non-survival cases and 38 % survival as described for overall population in this study as shown in table (8):

Table 8	Number	Percent
Survivor	38	38%
Non-Survivor	62	62%

According to RIFLE classification, the mortality rate was as follow:

**32.5%** in Non-ARF category

**68%** in RIFLE-R category

**75%** in RIFLE-I category

**93%** in RIFLE-F category

According to AKIN criteria, the mortality rate was as follow:

**31.5%** in Non-ARF category

**66%** in Stage 1 category

**75%** in Stage 2 category

**93%** in Stage 3 category

**Comparative analysis between Non-Survivor group and survivor group:**

There was statistically insignificant difference between both groups regarding age, gender, DM, HTN and HCC occurrence as shown in table (9):

Table 9	DEATH	Mean	±Std. Deviation	P VALUE
Age	Survivor	59.73	5.71	0.625
	Non-Survivor	58.91	9.24	
Gender		Male	Female	0.27
	Survivor	23	15	
DM		No DM	DM	0.589
	Survivor	23	15	
HTN		No HTN	HTN	0.589
	Survivor	33	5	
HCC		No HCC	HCC	0.485
	Survivor	30	2	
	Non-Survivor	50	8	

• **Univariate analysis for laboratory data:**

<b>Table 10</b>	DEATH	Mean	±Std. Deviation	P VALUE
BUN	Survivor	24.50	15.34	0.0001
	Non-Survivor	47.30	23.19	
Na	Survivor	135.42	5.55	0.0001
	Non-Survivor	126.72	6.31	
K	Survivor	4.29	0.39	0.20
	Non-Survivor	4.48	0.86	
AST	Survivor	54.86	33.98	0.037
	Non-Survivor	79.64	67.18	
ALT	Survivor	36.86	28.05	0.75
	Non-Survivor	35.30	21.29	
Albumin	Survivor	2.23	0.44	0.0001
	Non-Survivor	1.93	0.40	
Bilirubin	Survivor	3.53	2.20	0.0001
	Non-Survivor	8.65	6.57	
Hb	Survivor	8.96	1.27	0.35
	Non-Survivor	8.68	1.52	
WBC	Survivor	9.23	4.78	0.12
	Non-Survivor	11.16	6.78	
Platelets	Survivor	135.71	88.93	0.09
	Non-Survivor	111.11	57.91	
PT	Survivor	16.88	1.30	0.0001
	Non-Survivor	19.56	2.83	
INR	Survivor	1.51	0.13	0.0001
	Non-Survivor	1.77	0.27	
pH	Survivor	7.41	0.07	0.0001
	Non-Survivor	7.32	0.11	
PO <sub>2</sub>	Survivor	86.28	12.43	0.15
	Non-Survivor	81.08	20.18	
PCO <sub>2</sub>	Survivor	27.18	6.08	0.27
	Non-Survivor	25.85	5.63	
HCO <sub>3</sub>	Survivor	18.41	4.21	0.0001
	Non-Survivor	15.76	4.90	
Hct	Survivor	25.26	6.39	0.672
	Non-Survivor	24.67	6.85	
Creatinine at baseline	Survivor	0.77	0.22	0.0001
	Non-Survivor	1.08	0.23	
Creatinine on follow up	Survivor	1.02	0.63	0.0001
	Non-Survivor	2.42	1.21	

As described in table (10) Non-Survivor group had significantly higher serum creatinine level at baseline and during follow up, also higher BUN, serum bilirubin, PT and INR in comparison to Survivor group. The Non-Survivor group had a significantly lower serum sodium level, serum albumin, blood pH and HCO<sub>3</sub>.

There were statistically insignificant differences between both groups regarding values of ALT, Hb, Hct, WBCs, PLT, PO<sub>2</sub> and PCO<sub>2</sub>. Table (10)

**Length of hospital stay:**


Table 11	Survival	Mean	±Std. Deviation	P VALUE
LOS	Survivor	9.18	5.99	0.004
	Non-Survivor	13.08	6.53	

The Non-Survivor group had a significantly longer duration of hospital stay than the Survivor group as shown above in table (11).


All scoring systems studied in this study were highly predictive of poor outcome in cirrhotic patients at different cut-off points as studied by ROC curve analysis as shown in table (12):

**Cut-off points for prediction of mortality by different scoring systems:**

Table 12	Area under the curve	Mean of Cut off point	P value	PPV	NPV	Sensitivity	Specificity
RIFLE	0.798	Non ARF	0.0001	80%	78%	79%	72%
AKIN	0.801	Non ARF	0.0001	80%	78%	79%	72%



**Figure 27**



**The predictive death rates for RIFLE stage of renal failure as compared to other stages as shown in table (13) was significantly higher**

**90 %** at 17<sup>th</sup> day in group renal failure (RIFLE-F)  
**51%** at 11<sup>th</sup> day in group of renal injury (RIFLE-I)  
**50%** at 14<sup>th</sup> day of at risk group (RIFLE-R)  
**30 %** at 17<sup>th</sup> day for (non-ARF) and the *p* value was

Table 13	Predictive mortality	Descriptive mortality
Non-ARF	30%	32,5%
Risk	50%	68%
Injury	51%	75%
Failure	90%	93%

**The predictive death rates for AKIN stage of renal failure as compared to other stages as shown in table (14) was significantly higher**

**90 %** at 17<sup>th</sup> day in group renal failure (Stage 3)  
**51%** at 11<sup>th</sup> day in group of renal injury (Stage 2)  
**50%** at 14<sup>th</sup> day of at risk group (Stage 1)  
**30 %** at 17<sup>th</sup> day for (Non-ARF) and the *p* value was 0.016

Table 14	Predictive mortality	Descriptive mortality
Non-ARF	30%	31,5%
Stage 1	50%	66%
Stage 2	51%	75%
Stage 3	90%	93%

**4.Discussion**

This study was performed on 100 cirrhotic patients admitted to Intensive Care Unit in the hospital of Theodore Bilharz Research Institute. The objective of this study is to evaluate and compare RIFLE and AKIN criteria in evaluating AKI and predicting mortality in critically ill cirrhotic patients. The studied population was classified according to the primary outcome of this study (Hospital Mortality) into two main groups; Survivors and Non-Survivors.

There was statistically insignificant difference between both groups regarding age, gender distribution, DM, HTN and HCC occurrence on both groups. The Non-Survivor group had

significantly higher serum creatinine level at baseline and during follow up, also higher BUN, serum bilirubin, PT and INR in comparison to Survivor group. The Non-Survivor group had a significantly lower serum sodium level, serum albumin, blood PH and HCO<sub>3</sub>. There were also statistically insignificant differences between both groups regarding values of ALT, Hb, Hct, WBCs, PLT, PO<sub>2</sub> and PCO<sub>2</sub> (Tables 9, 10).

In this study, 60% of the ICU patients developed AKI; as defined by RIFLE classification; which was associated with increased mortality, compared with those who did not develop AKI. There were 40 Non-ARF patients, 22 RIFLE-R patients, 8 RIFLE-I patients and 30 RIFLE-F patients (Table 4). As defined by AKIN criteria, 62% of the ICU patients developed AKI which was associated with increased mortality, compared with those who did not develop AKI. There were 38 Non-ARF patients, 24 (Stage 1) patients, 8 (Stage 2) patients and 30 (Stage 3) patients (Table 5).

The overall mortality rate in this study was 62%, and is in agreement with previous reports indicating that cirrhotic patients admitted to an ICU have a very poor prognosis (11, 15, 16, 17, 18, and 19). This study identified that RIFLE classification and AKIN criteria on the first day of ICU admission was prognostically significant variables for critically ill cirrhotic patients. Importantly, even a mild degree of kidney dysfunction, RIFLE class risk or injury or AKIN Stage 1 or 2, were associated with elevated mortality rate, compared with patients who maintained normal function. In the present study, the hospital mortality rate of ICU patients was significantly higher for AKI patients (Risk, Injury, Failure) or (stages 1, 2, 3) versus non-AKI (Non-ARF) patients. We also found that there is stepwise increase in the mortality rate among RIFLE classes (32.5% in Non-ARF group, 68% in RIFLE-R group, 75% in RIFLE-I group and 93% in RIFLE-F group). Also there was a stepwise increase in mortality rate among AKIN classes (31.5% in Non-ARF group, 66% in Stage 1 group, 75% in Stage 2 group and 93% in Stage 3).

This study concluded that the predictive and descriptive mortality of RIFLE classification / AKIN classes are almost the same for Non-ARF and RIFLE-F/ Stage 3 categories while there was a little difference between predictive and descriptive mortality in the Risk / Stage 1 and Injury / Stage 2 categories of RIFLE / AKIN scores owing to the small number of patients in these groups and thus we recommend that this study be done on a larger number of patients.

We compared the overall incidence and severity classification of the RIFLE and AKIN criteria in this

study and found no significant differences. We also compared the clinical outcomes, specifically hospital mortality and duration of stay in ICU, and found no material differences.

These findings are relevant as they suggest that the proposed modifications to an already recognized and established definition/classification system (i.e. RIFLE criteria) fail to bring about material advantages. Moreover, our results suggest that future effort should focus more on the successful application and extend use of the RIFLE criteria to the randomization of patients in clinical trials or on its use as a surrogate marker of a clinically important outcome in clinical trials aimed as prevention or attenuation of renal injury.

From the previous studies and the current study, it is clear that RIFLE classification is a very important tool that can be used simply to stratify mortality in critically ill patients either medically (Cirrhosis, Sepsis, Respiratory failure, etc.) or surgically (patients whom admitted to ICU after major surgeries) and thus it is recommended to use it with other scoring systems to predict mortality among these patients.

Despite the encouraging results, this study has several limitations. First, this study was conducted at just one institution; consequently, the results may not be directly extrapolated to other patient populations. Second, the predictive accuracy of logistic regression models has its own limitations. Finally, the prognostic instruments were tested on patients already admitted to ICUs, rather than applied as a preadmission screening tool; this may have skewed the measured results.

## Conclusion

In conclusion, this study demonstrated that the prognosis for cirrhotic patients admitted to ICU is poor. Compared to the RIFLE criteria, the newly proposed AKIN criteria do not materially improve the sensitivity, robustness or predictive ability of the definition and classification of AKI in the first 24 h after admission to ICU. There would appear to be no justification at present for the introduction of a modified definition and classification system for AKI. Any future refinements to the RIFLE criteria (i.e. time constraint or urine output) should ideally occur only after prospective evaluation in clinical studies. Considering the economy and ease of implementation, we suggest that RIFLE classification can increase the accuracy of short-term prognosis in this homogeneous subset of patients.

**References:**

- 1) Jang JW. (2009) Current status of liver diseases in Korea: liver cirrhosis. *Korean J Hepatology*; 15(6) Suppl :40-49.
- 2) Iwakiri Y and Groszmann RJ (2006) The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. *Hepatology* 43:S121–S131.
- 3) Andrews P, Azoulay E, Antonelli M, *et al.* (2006) Year in review in intensive care medicine. 2005. I. Acute respiratory failure and acute lung injury, ventilation, hemodynamic, education, renal failure. *Intensive Care Med* 32:207–216.
- 4) Gines P, Cardenas A, Arroyo V, *et al.* (2004) Management of cirrhosis and ascites. *N Engl J Med* 350:1646–1654.
- 5) Schrier RW, Arroyo V, Bernardi M, *et al.* (1988) Peripheral arterial vasodilation hypothesis: a proposal for the initiation of sodium and water retention in cirrhosis. *Hepatology* 8:1151–1157.
- 6) Chen YC, Tsai MH, Hsu CW, *et al.* (2003) Role of serum creatinine and prognostic scoring systems in assessing hospital mortality in critically ill cirrhotic patients with upper gastrointestinal bleeding. *J Nephrol* 16:558–565.
- 7) Pugh RN, Murray-Lyon IM, Dawson JL, *et al.* (1973) Transection of the esophagus for bleeding esophageal varices. *Br J Surg* 60:646–649.
- 8) Vincent JL, Moreno R, Takala J, *et al.* (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis- Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Med* 22:707–710.
- 9) Kamath PS, Wiesner RH, Malinchoc M, *et al.* (2001) A model to predict survival in patients with end-stage liver disease. *Hepatology* 33:464–470.
- 10) Knaus WA, Draper EA, Wagner DP, *et al.* (1985) APACHE II: a severity of disease classification system. *Crit Care Med* 13:818–824.
- 11) Bellomo R, Kellum JA and Ronco C (2007) Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. *Intensive Care Med* 33:409–413.
- 12) Bellomo R, Ronco C, Kellum JA *et al.* Acute renal failure definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group. *Crit Care* 2004;8: R204–R212.
- 13) Abosaif NY, Tolba YA, Heap M *et al.* The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability. *Am J Kidney Dis* 2005; 46: 1038–1048.
- 14) Bagshaw S, George C, Bellomo R, A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. *Nephrol Dial Transplant* (2008) 23: 1569–1574.
- 15) Lin CY, Chen YC, Tsai FC, *et al.* (2006): RIFLE classification is predictive of short-term prognosis in critically ill patients with acute renal failure supported by extracorporeal membrane oxygenation. *Nephrol Dial Transplant* 21:2867–2873.
- 16) Tsai MH, Chen YC, Ho YP, *et al.* (2003): Organ system failure scoring system can predict hospital mortality in critically ill cirrhotic patients. *J Clin Gastroenterol* 37:251–257.
- 17) Cholongitas E, Senzolo M, Patch D, *et al.* (2006): Scoring systems for assessing prognosis in critically ill adult cirrhotics. *Aliment Pharmacol Ther* 24:453–464.
- 18) Tsai MH, Peng YS, Chen YC, *et al.* (2006) Adrenal insufficiency in critically ill cirrhotic patients with severe sepsis and septic shock. *Hepatology* 43:673–681.
- 19) Cosentino F, Chaff C and Piedmonte M (1994): Risk factors influencing survival in ICU acute renal failure. *Nephrol Dial Transplant* 9(4):179–182.

7/21/2014